LogicBio Therapeutics Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LogicBio Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LogicBio Therapeutics stock.
View analyst ratings for LogicBio Therapeutics or view top-rated stocks.

Wall Street analysts have given LogicBio Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but LogicBio Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

LogicBio Therapeutics saw a increase in short interest in February. As of February 26th, there was short interest totaling 827,300 shares, an increase of 22.1% from the February 11th total of 677,700 shares. Based on an average daily volume of 144,700 shares, the short-interest ratio is presently 5.7 days. Approximately 4.6% of the company's shares are short sold.
View LogicBio Therapeutics' Short Interest.

LogicBio Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for LogicBio Therapeutics.

LogicBio Therapeutics, Inc. (NASDAQ:LOGC) released its quarterly earnings results on Sunday, March, 14th. The company reported ($0.22) EPS for the quarter, topping the Zacks' consensus estimate of ($0.33) by $0.11. The firm earned $0.54 million during the quarter.
View LogicBio Therapeutics' earnings history.

LogicBio Therapeutics' stock was trading at $7.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, LOGC shares have decreased by 12.5% and is now trading at $6.16.
View which stocks have been most impacted by COVID-19.

3 equities research analysts have issued twelve-month target prices for LogicBio Therapeutics' shares. Their forecasts range from $17.00 to $20.00. On average, they expect LogicBio Therapeutics' stock price to reach $18.50 in the next twelve months. This suggests a possible upside of 200.3% from the stock's current price.
View analysts' price targets for LogicBio Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to LogicBio Therapeutics include Adaptimmune Therapeutics (ADAP), Inhibrx (INBX), Harpoon Therapeutics (HARP), Athira Pharma (ATHA), Osiris Therapeutics (OSIR), CEL-SCI (CVM), Vaxart (VXRT), DBV Technologies (DBVT), MeiraGTx (MGTX), Tarsus Pharmaceuticals (TARS), Compugen (CGEN), Agenus (AGEN), Solid Biosciences (SLDB), Poseida Therapeutics (PSTX) and Oyster Point Pharma (OYST).
View all of LOGC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other LogicBio Therapeutics investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), Acceleron Pharma (XLRN), Stoke Therapeutics (STOK), Precision BioSciences (DTIL), Micron Technology (MU), Homology Medicines (FIXX) and II-VI (IIVI).

(LOGC) raised $77 million in an initial public offering (IPO) on Friday, October 19th 2018. The company issued 5,800,000 shares at $12.50-$14.00 per share. Jefferies, Barclays and William Blair served as the underwriters for the IPO and Chardan was co-manager.

LogicBio Therapeutics trades on the NASDAQ under the ticker symbol "LOGC."

Shares of LOGC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LOGC stock can currently be purchased for approximately $6.16.

LogicBio Therapeutics has a market capitalization of $197.28 million. The company earns $-40,130,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis.

LogicBio Therapeutics employs 39 workers across the globe.

The official website for LogicBio Therapeutics is www.logicbio.com.

LogicBio Therapeutics is headquartered at 65 HAYDEN AVENUE 2ND FLOOR, LEXINGTON MA, 02421.

LogicBio Therapeutics' mailing address is 65 HAYDEN AVENUE 2ND FLOOR, LEXINGTON MA, 02421. The company can be reached via phone at 617-245-0399 or via email at [email protected]